NSE · Healthcare · Drug Manufacturers - General
EPS came in at 50.67 against a street estimate of 39.00 — a beat of 29.9%.
with an average price target of ₹4,339.67.
| Holder | Stake |
|---|---|
| LIFE INSURANCE CORPORATION OF INDIA - P & GS Fund | 5.95% |
| Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund | 4.17% |
| General Insurance Corporation of India | 2.56% |
| Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Large Cap Fund | 2.04% |
| Bajaj Life Insurance | 1.44% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call SANOFI INDIA LIMITED – INVESTOR CALL SUMMARY August 5, 2026 --- HEADLINE NUMBERS • Q2 2026 Total Income: +7% YoY growth • Q2 2026 Domestic Sales: + | 2026-08-10 |
| Quarterly results · Q1 FY27 SANOFI INDIA LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue from Operations: ₹4,377 million (8% domestic growth, 6% total growth vs | 2026-08-04 |
| Quarterly results · Q4 FY26 SANOFI INDIA LIMITED – Q1 FY2026 SUMMARY HEADLINE NUMBERS • Q1 FY2026 Revenue from Operations: ₹4,723 million (vs ₹4,198 million in Q4 FY2025; vs ₹5 | 2026-04-28 |
| Annual report FY2025 SANOFI INDIA LIMITED – FY 2025 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from operations: ₹18,374 million (FY 2024: ₹20,132 million) – | 2026-04-02 |
| Q3 FY26 earnings call SANOFI INDIA LIMITED – INVESTOR CALL SUMMARY Financial Results for Quarter and Year Ended December 31, 2025 --- HEADLINE NUMBERS • Full Year 2025 D | 2026-03-05 |
| Investor presentation · Q3 FY26 SANOFI INDIA LIMITED - Q4 & FY2025 INVESTOR SUMMARY HEADLINE NUMBERS • Total Income FY2025: ₹20,297 million, down 9% vs ₹18,571 million in FY2024 • | 2026-02-26 |
| Quarterly results · Q3 FY26 SANOFI INDIA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Total Revenue from Operations (FY 2025): ₹18,374 million (down from ₹20,132 million in FY | 2026-02-25 |
| Q2 FY26 earnings call SANOFI INDIA LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q3 FY2025 (Quarter ended 30 Sept 2025): Profit Before Tax (PBT) showed double-digit growt | 2025-11-04 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹75 / share ex-date Nov 5, 2026 | 2026-11-05 |
| Dividend | ₹48 / share ex-date Apr 22, 2026 | 2026-04-22 |
| Dividend | ₹75 / share ex-date Nov 7, 2025 | 2025-11-07 |
| Announcement | Date |
|---|---|
| Interim dividend of Rs. 75 per equity share declared Sanofi India reported a strong third quarter of 2026, with results approved for the quarter and nine months ended September 30. Total sales grew 4% year-on-year, while domestic sales increas | 2026-10-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sanofi India Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.